Graham Holdings Company spent the second quarter of 2026 quietly reshuffling its portfolio while posting modest operating gains that were overwhelmed by a one-time pension settlement. Net income attributable to common shares reached $281.1 million, up from $36.7 million a year earlier. A $137.0 million non-cash settlement gain tied to a retiree annuity purchase and a $69.6 million tax benefit from the Kaplan Languages Group divestiture together accounted for more than three-quarters of that headline number. Stripping out the special items gives an adjusted earnings per share of $19.46. That compares to $14.33 in the second quarter of the prior year, which is the cleaner read on the operating business. The underlying message is that the diversified model continues to throw off cash while the parent deploys that cash in two reinforcing directions, namely aggressive share repurchases and continued bolt-on acquisitions in healthcare and manufacturing.
The share price at the time of this report sits near $1,117, well off the fifty-two week high of $1,262 reached earlier in the cycle. It is also comfortably above the $929 fifty-two week low. That pricing puts Graham in the multi-billion-dollar market-cap range on a comparatively tiny share count, which is the result of years of buybacks. The company continues to allocate meaningful capital to repurchase stock at a steady cadence, and the buyback is the single most important driver of the per-share metrics. The valuation reads modestly on a trailing P/E near 9 and a forward P/E near 17, a wide gap that reflects the heavy load of non-operating items in current earnings. A balance sheet that holds $1,297.4 million of cash, marketable equity securities and other investments against $900.4 million of total debt gives the company a net cash position. That is before counting the $812.1 million of net unrealized gains already inside the marketable equity securities portfolio. For an investor, the core question is whether the buyback-heavy capital return model plus the bolt-on healthcare and manufacturing deals can keep producing the steady adjusted earnings growth that the multiple seems to demand.
The strongest argument against the bull case is that three of the seven reporting divisions saw operating income decline year over year, including healthcare and automotive, even as their revenue lines grew. The Kaplan Languages Group sale closed on May 1, 2026, removing a structurally low-margin international English-language business. The deal also pulled roughly $20 million of annualized revenue out of the Kaplan International segment. The Pathways businesses in the U.K., Australia and the U.S. are still contracting. The manufacturing segment posted 39% revenue growth on the back of the July 2025 Arconic acquisition. Operating income there fell 6% in the second quarter, even as the top line surged. The forward variable to watch is whether adjusted operating cash flow continues to grow faster than reported revenue, which it did in the first half. The next phase of buybacks, at an average price above $1,100, is the second variable, since the program only compounds if the per-share economics of the repurchase stay attractive.